| [1] |
Keung EZ, Raut CP.Management of Gastrointestinal Stromal Tumors[J]．Surg Clin North Am，2017，97(2)：437-452.
|
| [2] |
Demetri GD, von Mehren M, Antonescu CR，et al.NCCN Task Force report: management of patients with gastrointestinal stromal tumors[J]．J Nati Compr Canc Netw，2010，8 Suppl 2：S1-S41；quiz S42－S44.
|
| [3] |
Seifert AM, Zeng S, Zhang JQ，et al.PD－1/PD－L1 Blockade Enhances T－cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors[J]．Clin Cancer Res，2017，23(2)：454-465.
|
| [4] |
Sodergren SC, White A, Efficace F，et al.Systematic review of the side effects associated with tyrosine kinase inhibitors used in the treatment of gastrointestinal stromal tumours on behalf of the EORTC Quality of Life Group[J]．Criti Rev Oncoln Hematol，2014，91(1)：35-46.
|
| [5] |
Zhao R, Song Y, Wang Y, et al. PD－1/PD－L1 blockade rescue exhausted CD8＋ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTORsignalling pathway[J]. Cell Proliferation. 2019 Feb 03.
|
| [6] |
Bertucci F, Finetti P, Mamessier E, et al. PDL1 expression is an independent prognostic factor in localized GIST[J]. OncoImmunology, 2015, 4(5)：e1002729.
|
| [7] |
Joensuu H．Risk stratification of patients diagnosed with gastroin－testinal stromal tumor[J]．Hum Pathol，2008，39(10)：1411-1419.
|
| [8] |
Fletcher CD, Berman JJ, Corless C，et al.Diagnosis of gastrointestinal stromal tumors: a consensus approach[J]．Int J Surg Pathol，2002，10(2)：81-89.
|
| [9] |
Zhou Y, Hu W, Chen P，et al.Ki67 is a biological marker of malignant risk of gastrointestinal stromal tumors[J]．Medicine，2017，96(34)：e7911.
|
| [10] |
Zhi X, Jiang B, Yu J，et al.Prognostic role of microscopically positive margins for primary gastrointestinal stromal tumors: a systematic review and meta－analysis[J]．Sci Rep，2016，6：21541.
|
| [11] |
Joensuu H, Vehtari A, Riihimaki J，et al.Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population－based cohorts[J]．Lancet Oncol，2012，13(3)：265-274.
|
| [12] |
Dematteo RP, Gold JS, Saran L，et al.Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST)[J]．Cancer，2008，112(3)：608-615.
|
| [13] |
Miettinen M, Lasota J．Gastrointestinal stromal tumors: pathology and prognosis at different sites[J]．Semin Diagn Pathol，2006，23(3)：70-83.
|
| [14] |
Rutkowski P, Wozniak A, De Rbiec－Rychter M，et al.Clinical utility of the new American Joint Committee on Cancer staging system for gastrointestinal stromal tumors: current overall survival after primary tumor resection[J]．Cancer，2011，117(21)：4916-4924.
|
| [15] |
Boye K, Berner JM, Hompland I，et al.Genotype and risk of tumour rupture in gastrointestinal stromal tumour[J]．Br J Surg，2018，105(2)：e169-e175.
|
| [16] |
Nishida T, Cho H, Hirota S，et al.Clinicopathological Features and Prognosis of Primary GISTs with Tumor Rupture in the Real World[J]．Ann Surg Oncol，2018，25(7)：1961-1969.
|
| [17] |
Bischof DA, Kim Y, Behman R，et al.A nomogram to predict disease－free survival after surgical resection of GIST[J]．J Gastrointest Surg，2014，18(12)：2123-2129.
|
| [18] |
Zhao B, Zhang J, Mei D，et al.The assessment of different risk classification systems for gastrointestinal stromal tumors (GISTs): the analytic results from the SEER database[J]．Scand J Gastroenterol，2018，53(10－11)：1319-1327.
|
| [19] |
Vicente E, Quijano Y, Ielpo B，et al.Robot－assisted resection of gastrointestinal stromal tumors (GIST): A single center case series and literature review[J]. Int J Med Robot, 2016，12(4)：718-723.
|
| [20] |
Von Mehren M, Randall R L, Benjamin R S, et al. Gastrointestinal Stromal Tumors, Version 2.2014[J]. Journal of the National Comprehensive Cancer Network, 2014, 12(6)：853-862.
|
| [21] |
Demetri GD, Von Mehren M, Antonescu CR，et al.NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors[J]．J Nati Compr Canc Netw，2010，8 Supply 2：S1-S41；quiz S42－S44.
|
| [22] |
Hu J, Or BH, Hu K，et al.Comparison of the post－operative outcomes and survival of laparoscopic versus open resections for gastric gastrointestinal stromal tumors: A multi－center prospective cohort study[J]．Int J Surg，2016，33 Pt A：65-71.
|
| [23] |
Ford SJ, Gronchi A．Indications for surgery in advanced/metastatic GIST[J]. Eur J Cancer，2016，63：154-167.
|
| [24] |
ESMO/European Sarcoma Network Working Group.Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow－up[J]．Ann Oncol，2014，25 supply 3：iii21-iii26.
|
| [25] |
Mccarter MD, Antonescu CR, Ballman KV，et al.Microscopically Positive Margins for Primary Gastrointestinal Stromal Tumors: Analysis of Risk Factors and Tumor Recurrence[J]．J Am Coll Surg，2012，215(1)：53-59；discussion 59－60.
|
| [26] |
Lu J, Dai Y, Zheng HL，et al.What is the appropriate duration of adjuvant imatinibmesylate treatment for primary gastrointestinal stromal tumors classified according to the strict definition of tumor rupture[J]．Medicine，2019，98(3)：e14177.
|
| [27] |
Boye K, Berner JM, Hompland I，et al.Genotype and risk of tumour rupture in gastrointestinal stromal tumour[J]．Br J Surg，2018，105(2)：e169-e175.
|
| [28] |
Holmebakk T, Hompland I, Bjerkehagen B，et al.Recurrence－free survival after resection of gastric gastrointestinal stromal tumors classified according to a strict definition of tumor rupture: a population－based study[J]．Ann Surg Oncol，2018，25(5)：1133-1139.
|
| [29] |
HoLmebakk T, Bjerkehagen B, Boye K，et al.Definition and clinical significance of tumour rupture in gastrointestinal stromal tumours of the small intestine[J]．Br J Surg，2016，103(6)：684-691.
|
| [30] |
Liu X, Qiu H, Zhang P，et al. Ki－67 labeling index may be a promising indicator to identify "very high risk" gastrointestinal stromal tumor (GIST): a multicenter retrospective study of 1022 patients[J]．Hum Pathol，2018，74：17-24.
|
| [31] |
Sozutek D, Yanik S, Akkoca AN，et al.Diagnosticandprognosticroles of DOG1 and Ki67，inGISTpatientswithlocalizedoradvanced/metastatic disease[J]．Int J Clin Exp Med，2014，7(7)：1914-1922.
|
| [32] |
Zhao WY, Xu J, Wang M，et al.Prognostic value of Ki67 index in gastrointestinal stromal tumors[J]．Int J Clin Exp Pathol，2014，7(5)：2298-2304.
|
| [33] |
Gill AJ.Succinate dehydrogenase (SDH) and mitochondrial driven neoplasia[J]．Pathology，2012，44(4)：285-292.
|
| [34] |
Gill AJ.Succinate dehydrogenase (SDH)－deficient neoplasia[J]．Histopathology，2018，72(1)：106-116.
|
| [35] |
Gill AJ, Chou A, Vilain R，et al. Immunohistochemistry for SDHB divides gastrointestinal stromal tumors (GISTs) into two distinct types[J]．Am J Surg Pathol，2010，34(5)：636-644.
|
| [36] |
Mason EF, Hornick JL.Conventional risk stratification fails to predict progression of succinate dehydrogenase－deficient gastrointestinal stromal tumors: a clinicopathologic study of 76 cases[J]．Am J Surg Pathol，2016，40(12)：1616-1621.
|
| [37] |
Miettinen M, Killian JK, Wang ZF，et al.Immunohistochemical loss of succinate dehydrogenase subunit A (SDHA) in gastrointestinal stromal tumors (GISTs) signals SDHA germline mutation[J]．Am J Surg Pathol，2013，37(2)：234-240.
|
| [38] |
Powers JF, Cochran B, Baleja JD，et al.A unique model for SDH－deficient GIST: an endocrine－related cancer[J]．Endocr Relat Cancer，2018，25(11)：943-954.
|
| [39] |
Corless CL, Barnett CM, Heinrich MC.Gastrointestinal stromal tumours: origin and molecular oncology[J]．Nat Rev Cancer，2011，11(12)：865-878.
|
| [40] |
Vernuccio F, Taibbi A, Picone D，et al.Imaging of Gastrointestinal Stromal Tumors: From Diagnosis to Evaluation of Therapeutic Response[J]．Anticancer Res，2016，36(6)：2639-2648.
|